Compassionate use of abiraterone and cabazitaxel. First experiences in docetaxel-pretreated castration-resistant prostate cancer patients;Abiraterone- und cabazitaxel-härtefallprogramm. Erste klinische erfahrungen bei docetaxel-vorbehandelten kastrationsresistenten prostatakarzinompatienten

Urologe - Ausgabe A

Volumn 51, Issue 3, 2012, Pages 390-397

  Heck, M M ^a   Hoppner M ^a   Horn, T ^a   Thalgott, M ^a   Gschwend, J E ^a   Retz, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Abiraterone; Androstenols; Cabazitaxel; Drug therapy; Prostate cancer

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ANEMIA; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; POLYNEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION;

AGED; ANDROSTENOLS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPASSIONATE USE TRIALS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ORCHIECTOMY; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863776392     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-012-2804-y     Document Type: Article

References (7)

1. Danila DC, Morris MJ, de Bono JS et al (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28(9):1496-1501
2. Bono JS, Oudard S, Ozguroglu M de et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995-2005
3. Bono JS de, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147-1154
4. Petrylak DP, Macarthur R, O'Connor J et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513-1520 (Pubitemid 39315318)
5. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148-1159
6. Tannock IF, Osoba D, Stockler MR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502-1512 (Pubitemid 39315317)
7. Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756-1764 (Pubitemid 26185452)